05.01.07
A clinical trial conducted by the Nutritional Sciences department of the Chinese Academy of Sciences demonstrated that a structured intervention program that includes Abbott Nutrition’s (Montreal, Canada) nutritional supplement Glucerna along with blood glucose monitoring, diabetes education and dietary and nutrition modification significantly reduced key metabolic markers—glycosylated hemoglobin (HbA1c), fasting plasma glucose, systolic and diastolic blood pressure, weight and waist circumference—in overweight patients with type 2 diabetes. These findings were published in the American Diabetes Association 66th Scientific Sessions Abstract Book.
The randomized, controlled clinical trial was conducted on 150 patients in Shanghai, China, over a 6-month period. For 100 patients, blood glucose monitoring, caloric control using Glucerna once daily as a meal replacement, diabetes education and dietary modification were added to the usual diabetes care given to the 50 patients in the control group.
After 6 months, patients in the intervention group had reduced their weight from an average of 75.7 kg to 72.8 kg, their fasting glucose from 8.62 mmol/L to 7.39 mmol/L and their HbA1c levels from 7.1 to 6.3. Systolic blood pressure was reduced from an average of 131.2 to 123.7 and diastolic blood pressure from 87.0 to 83.8. Patients in the control group reduced their weight from an average of 75.6 kg to 73.8 kg, but did not see significant reductions in any other key metabolic markers.
Glucerna contains a specialized, slowly released carbohydrate system formulated to provide lower peak glucose levels than a standard medical nutritional liquid or snack bar.
The randomized, controlled clinical trial was conducted on 150 patients in Shanghai, China, over a 6-month period. For 100 patients, blood glucose monitoring, caloric control using Glucerna once daily as a meal replacement, diabetes education and dietary modification were added to the usual diabetes care given to the 50 patients in the control group.
After 6 months, patients in the intervention group had reduced their weight from an average of 75.7 kg to 72.8 kg, their fasting glucose from 8.62 mmol/L to 7.39 mmol/L and their HbA1c levels from 7.1 to 6.3. Systolic blood pressure was reduced from an average of 131.2 to 123.7 and diastolic blood pressure from 87.0 to 83.8. Patients in the control group reduced their weight from an average of 75.6 kg to 73.8 kg, but did not see significant reductions in any other key metabolic markers.
Glucerna contains a specialized, slowly released carbohydrate system formulated to provide lower peak glucose levels than a standard medical nutritional liquid or snack bar.